Headlines about CoLucid Pharmaceuticals (NASDAQ:CLCD) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CoLucid Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 43.9159206211039 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

COPYRIGHT VIOLATION NOTICE: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/28/colucid-pharmaceuticals-clcd-receives-daily-news-impact-rating-of-0-18.html.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Insider Buying and Selling by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

Receive News & Stock Ratings for CoLucid Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.